Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers
Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...
Business Wire15 天
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...
Investing6 天
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights
On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...
Business Wire8 天
Amneal to Participate at Upcoming Investor Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief ...